semaglutide amino | C187H291N45O59 | CID 56843331 Overview of Tirzepatide and Semaglutide

What clinicians consider when advising against GLP-1 use during breastfeeding Lack of large, controlled lactation safety trials Unknown effects on infant growth or neurodevelopment Uncertainty about effects on milk supply or composition Elective nature of GLP-1 therapy for weight loss Availability of safer alternatives after breastfeeding ends Why FDA and medical guidance remains cautious FDA and specialty guidance emphasize caution during breastfeeding for several consistent reasons: Insufficient data: FDA labeling states there are inadequate data on GLP-1 medication effects in breastfed infants.,, Milk supply unknowns: It is not known whether GLP-1 medications affect milk supply (volume) or milk composition., Infant vulnerability: Early infancy is a sensitive developmental period, increasing caution when medication effects are unknown. Elective vs essential use: For weight management, potential maternal benefit often does not outweigh theoretical infant risk.,, Do semaglutide and tirzepatide pass into breast milk

The inclusion of benzyl alcohol allows the solution to remain usable for a limited period after opening, helping support safe handling practices in controlled environments

It does not advertise, offer or recommend Ipamorelin and contains no dosing, cycling, preparation, administration or personal use instructions

doi:10.1007/s00213-020-05629-2 84 Nery, F